Regeneron Pharmaceuticals, Inc.
REGN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $58,262,186 | $55,177,500 | $67,672,341 | $76,860,407 |
| - Cash | $2,506,400 | $1,995,800 | $3,090,200 | $2,488,200 |
| + Debt | $2,705,500 | $2,705,100 | $2,704,800 | $2,704,400 |
| Enterprise Value | $58,461,286 | $55,886,800 | $67,286,941 | $77,076,607 |
| Revenue | $3,754,300 | $3,675,600 | $3,028,700 | $3,789,200 |
| % Growth | 2.1% | 21.4% | -20.1% | – |
| Gross Profit | $3,232,700 | $3,145,400 | $2,564,400 | $3,223,800 |
| % Margin | 86.1% | 85.6% | 84.7% | 85.1% |
| EBITDA | $1,919,300 | $1,657,400 | $1,040,600 | $1,095,000 |
| % Margin | 51.1% | 45.1% | 34.4% | 28.9% |
| Net Income | $1,460,000 | $1,391,600 | $808,700 | $917,700 |
| % Margin | 38.9% | 37.9% | 26.7% | 24.2% |
| EPS Diluted | 13.62 | 12.81 | 7.27 | 8.06 |
| % Growth | 6.3% | 76.2% | -9.8% | – |
| Operating Cash Flow | $1,618,700 | $1,144,400 | $1,045,100 | $1,262,800 |
| Capital Expenditures | -$201,400 | -$176,800 | -$271,500 | -$267,000 |
| Free Cash Flow | $1,417,300 | $967,600 | $773,600 | $995,800 |